Additional file 1 of Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's disease

Additional file 1 (DOCX 10738 KB). Supplementary Methods. Fig. S1. 1H NMR spectra of synthesized PPR. Fig. S2. Cell segmentation of Fig. 2. Fig. S3-S5. Images for cellular uptake. Fig. S6. Quantitative cellular uptake of different formulations by bEnd.3, N2a, and BV-2 cells at 3 h determined from flow cytometry. Fig. S7. All Western blot of BACE1 protein expression levels in both N2a and BV-2 cells treated with different formulation. Fig. S8. Cell segmentation of Fig. 3. Fig. S9. In vivo imaging of WT mice treated with different formulation. Fig. S10. No Cy5 fluorescence signal detected in the DG region of brain sections of mice with PBS treatment. Fig. S11. No Cy5 fluorescence signal detected in the CA1 region of brain sections of mice with PBS treatment. Fig. S12. No Cy5 fluorescence signal detected in the CA3 region of brain sections of mice with PBS treatment. Fig. S13. Fluorescence determining the accumulation of Cy5-labeled PPR@siRNA and PP@siRNA in the CA3 region of brain sections. Fig. S14. Additional behavioral metrics. Fig. S15. All Western blot for BACE1 and MBP of mice. Fig. S16. Immunofluorescence staining of microglia with Iba1 (green) in the cortex region of mice from different groups. Fig. S17. Immunofluorescence staining of astrocyte with GFAP (red) in the cortex region of mice from different groups. Fig. S18. Representative data for hematoxylin and eosin staining in major organs of mice from different groups. Table S1. qPCR primer sequences